# Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer

> **NCT00116506** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 35 (—)

## Conditions studied

- Colorectal Cancer
- Neoplasm Metastasis

## Interventions

- **DRUG:** erlotinib
- **DRUG:** FOLFOX
- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT00116506
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 35 (—)
- **Last updated:** 2007-12-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00116506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00116506, "Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00116506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*